Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Graft Versus Host Disease
Related studies linked through entity extraction aliases.
Efficacy of Low-dose PT-Cy for Prevention of GVHD in Ambulatory Allogeneic HSCT
- Status
- COMPLETED
- Phase
- PHASE2
Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
- Status
- RECRUITING
- Phase
- PHASE2
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
- Status
- RECRUITING
- Phase
- PHASE1
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
- Status
- RECRUITING
- Phase
- PHASE2
Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation
- Status
- RECRUITING
- Phase
- PHASE3
Posaconazole Tablet As Primary Prophylaxis of HSCT Patients with Gastrointestinal GVHD
- Status
- ENROLLING_BY_INVITATION
- Phase
- N/A
Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation
- Status
- RECRUITING
- Phase
- PHASE2
Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
- Status
- WITHDRAWN
- Phase
- N/A
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
- Status
- RECRUITING
- Phase
- PHASE1
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
- Status
- RECRUITING
- Phase
- N/A
Intestinal Microbiome-based Research for the Prevention of Acute GVHD
- Status
- UNKNOWN
- Phase
- PHASE2
Expressive Writing in GVHD
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
- Status
- TERMINATED
- Phase
- NA
Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD
- Status
- WITHDRAWN
- Phase
- PHASE2
A Prospective, Open Label, Dose-escalation, SAD/MAD, Multicenter, 24weeks, Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of Investigational Product (VM-001) in Patients With Graft-versus-host Disease(GvHD)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
- Status
- TERMINATED
- Phase
- PHASE3
Comparison of PT-Cy at a Dose of 25 mg/kg/Day and PT-Cy at a Dose of 50 mg/kg/Day in GVHD Prophylaxis
- Status
- UNKNOWN
- Phase
- PHASE3